Uterotonic Prophylaxis Trial
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | March 2015 |
| Contact: | Jennifer Kerns, MD |
| Email: | Jennifer.Kerns@ucsf.edu |
| Phone: | (510)502-4340 |
Excessive bleeding after dilation and evacuation (D&E) requiring interventions is common,
occurring in approximately 30% of cases at one large abortion-providing clinic. Uterotonic
prophylaxis at the time of D&E, particularly with methylergonovine maleate (MM), is a common
practice among D&E providers despite nearly no evidence for its efficacy. Finding ways to
decrease excessive bleeding after D&E has the potential both to improve patient safety and
to reduce costs of provider-initiated interventions. The investigators propose a randomized,
controlled trial to investigate the efficacy of MM prophylaxis versus placebo in decreasing
excessive bleeding measured by a composite outcome among women undergoing D&E at 20 to 24
weeks.
occurring in approximately 30% of cases at one large abortion-providing clinic. Uterotonic
prophylaxis at the time of D&E, particularly with methylergonovine maleate (MM), is a common
practice among D&E providers despite nearly no evidence for its efficacy. Finding ways to
decrease excessive bleeding after D&E has the potential both to improve patient safety and
to reduce costs of provider-initiated interventions. The investigators propose a randomized,
controlled trial to investigate the efficacy of MM prophylaxis versus placebo in decreasing
excessive bleeding measured by a composite outcome among women undergoing D&E at 20 to 24
weeks.
Inclusion Criteria:
- Between 20 wks 0 days gestation and 24 wks 0 days gestation
- English or Spanish speaking
- BP before injection 140/90 or below
- 18 years old or over
We found this trial at
1
site
Click here to add this to my saved trials
